The National Cancer Institute (NCI) supports the development of translational nanotechnologies with applications in the diagnosis and therapy of cancer through its Alliance for Nanotechnology in Cancer program. Cancer nanotechnology is widely viewed as a promising and highly innovative field, with the potential for transformative scientific advancements and practical applications relevant to cancer.
The NCI participates in the NIH Parent Program Announcement PA-14-015 "Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)".
Through this Notice, the NCI announces that eligible applicant institutions and applicants are welcome to submit T32 applications to PA-14-015 that request support for the development and operation of cancer nanotechnology research training programs. Such programs would be expected to educate graduate students and postdoctoral fellows in the multi-disciplinary field of cancer nanotechnology research. The targeted graduate student and post-doctoral researchers should have broad academic and research backgrounds, including, but not limited to, the disciplines of medicine, biology, and/or other health sciences as well as in the physical sciences, chemistry, and engineering. All requirements of PA-14-015 would need to be followed in any application (and award) that proposes to develop and conduct a cancer nanotechnology research training program.
The NCI plans to designate up to $2 million per year over 5 years in total to fund T32 applications which are submitted to PA-14-015 and are focused on training in the area of cancer nanotechnology research.
For more information, please visit: